 |
|
New study suggests potential for a broadly-protective HIV vaccine
May 30, 2007USU researchers find broad-spectrum defense against multiple strains of HIV-1
BETHESDA, Md. -- New research conducted at the Uniformed Services University of the Health Sciences (USU) suggests that it may be possible to develop a vaccine that protects against the myriad strains of the HIV virus. HIV is extremely variable, so an effective vaccine may need to stimulate the body to produce cross-reactive antibodies that will neutralize multiple viral strains. These results demonstrate that induction of truly broad-spectrum neutralizing antibodies may be an achievable goal. This groundbreaking study titled: "Extensively Cross-Reactive Anti-HIV-1 Neutralizing Antibodies Induced by gp140 Immunization" appears this week in the Early Edition of Proceedings of the National Academy of Sciences http://www.pnas.org/papbyrecent.shtml.
To be effective, an HIV vaccine must induce the body to produce cross-reactive antibodies that can neutralize multiple strains. USU Professors CAPT Gerald Quinnan, Jr., M.D., USPHS, and Christopher Broder, Ph.D., and their colleagues at USU attempted to elicit these broad-range antibodies in an animal model by immunizing with a particular HIV-1 surface protein, designated R2 gp140, and an immune response-boosting component. The researchers tested antibodies generated by the immunizations to determine their effectiveness in neutralizing the infectivity of a variety of HIV-1 strains. Antibodies produced as a result of immunization neutralized all 48 strains of HIV-1 tested. The results are encouraging for vaccine development, because they showed that it is possible to elicit a broad-spectrum antibody response.
Henry M. Jackson Foundation for the Advancement of Military Medicine
Henry M. Jackson Foundation for the Advancement of Military Medicine
HIV Vaccine Current Events and HIV Vaccine News RSSNew findings suggest strategy to help generate HIV-neutralizing antibodies
New discoveries about anti-HIV antibodies may bring researchers a step closer to creating an effective HIV vaccine, according to a new paper co-authored by scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Global challenges and opportunities in fighting HIV/AIDS and neglected diseases
Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs.
HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study
In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand.
New chemically-activated antigen could expedite development of HIV vaccine
Scientists working to develop a vaccine for the human immunodeficiency virus (HIV) report they have created the first antigen that induces protective antibodies capable of blocking infection of human cells by genetically-diverse strains of HIV.
Researchers induce HIV-neutralizing antibodies that recognize HIV-1 envelope protein, lipids
For the first time, researchers have experimentally induced antibodies that neutralize HIV-1 and simultaneously recognize both HIV-1 envelope protein and lipids.
College students who feel 'invincible' unlikely to accept vaccines, MU researcher finds
Vaccines to protect against sexually transmitted diseases, including HIV and herpes, are being developed and may soon be available to college students.
Penn-Wistar team gains insight into HIV vaccine failure
A team of researchers from The Wistar Institute and the University of Pennsylvania reports new evidence refuting a popular hypothesis about the highly publicized failure in 2007 of the Merck STEP HIV vaccine study that cast doubt on the feasibility of HIV-1 vaccines.
NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine
Most vaccines that protect against viruses generate infection-fighting proteins called antibodies that either block infection or help eliminate the virus before it can cause disease.
New contraceptive device is designed to prevent sexual transmission of HIV
Researchers from Weill Cornell Medical College have published results showing that a new contraceptive device may also effectively block the transmission of the HIV virus.
Novel vaccine approach offers hope in fight against HIV
A research team may have broken the stubborn impasse that has frustrated the invention of an effective HIV vaccine, by using an approach that bypasses the usual path followed by vaccine developers.
More HIV Vaccine Current Events and HIV Vaccine News Articles
 |
Shots in the Dark: The Wayward Search for an AIDS Vaccine by Jon Cohen (Author) "[A]n important book not only for the now but for the future of this epidemic and those to come."—Dr. Robert Gallo When scientists proved in 1984 that HIV causes AIDS, a vaccine race spun into action. But the sprint to develop an AIDS vaccine now more closely resembles a crawl. Jon Cohen elucidates the forces that have hindered the search: unforeseen scientific obstacles, clashing personalities, the uncertain marketplace, haphazard political organization, and serious ethical dilemmas. Beyond a powerful critique, Cohen also offers specific recommendations for accelerating the effort. 6 pages of b/w photographs.. |
|
The First Decade of Safe and Effective HIV Vaccines by Jeremiah O. A. Abalaka (Author) | |
 |
HIV And Molecular Immunity: Prospects for the AIDS Vaccine by Omar Bagasra (Author) How old is the AIDS virus (HIV-1) and where did it come from? Is it the result of a recombinant event in simian immunodeficiency viruses (SIVs)? Why do SIVs naturally occur in a variety of nonhuman African primates without inducing AIDS in their natural hosts? HIV-1 has devastated human society, although chimpanzees carry an SIV that is genetically almost identical to HIV-1 but causes no known illness in these great apes. How are Chimpanzees immune to HIV-1? Can humans acquire this immunity? Why do most newborns infected with HIV-1 in utero or during birth become long-term non-progressors while 20% rapidly develop AIDS and die in less than a year? Why are some adults asymptomatic for over 10 years after infection? Dr. Omar Bagasra, an eminent molecular biologist, immunologist,... |
 |
The Search for an AIDS Vaccine: Ethical Issues in the Development and Testing of a Preventive HIV Vaccine (Medical Ethics) by Christine Grady (Author) National Institute of Nursing Research. Single-author review of the current state of HIV vaccine research from the perspective of the ethical aspects of human subject research. |
|
Immune Response Bears Brunt of Partner's Pullout.(Agouron Pharmaceuticals will no longer fund development of its experimental HIV vaccine, Remune)(Brief ... An article from: San Diego Business Journal by Marion Webb (Author) This digital document is an article from San Diego Business Journal, published by CBJ, L.P. on July 16, 2001. The length of the article is 556 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Immune Response Bears Brunt of Partner's Pullout.(Agouron Pharmaceuticals will no longer fund development of its experimental HIV vaccine, Remune)(Brief Article) Author: Marion Webb Publication: San Diego Business Journal (Magazine/Journal) Date: July 16, 2001 Publisher: CBJ, L.P. Volume: 22 Issue: 29 Page: 9 Article Type: Brief Article Distributed by Thomson... | |
 |
HIV/Vaccine Needs - Procs of the Intl Seminar on Planetary Emergencies, 24th Session by Richard C. Ragaini (Author), Ragaini Richard (Author) This exploration of HIV/AIDS vaccine needs is taken from the 24th Session of the International Seminar on Nuclear War and Planetary Emergencies. Topics covered include: biotechnology; neuropathologies; development; sustainability; energy; water; and more. |
|
U.S. AWARDS $15 MIL TO GEOVAX HIV/AIDS VACCINE PROGRAM.: An article from: Biotech Business by Gale Reference Team (Author) This digital document is an article from Biotech Business, published by Thomson Gale on November 1, 2007. The length of the article is 573 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: U.S. AWARDS $15 MIL TO GEOVAX HIV/AIDS VACCINE PROGRAM. Author: Gale Reference Team Publication: Biotech Business (Newsletter) Date: November 1, 2007 Publisher: Thomson Gale Volume: 20 Issue: 11 Page: NA Distributed by Thomson... | |
|
Ethical Issues in HIV Vaccine Trials by Thomas A. Kerns (Author) | |
|
Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues (S. Hrg.) by United States (Other Contributor) | |
 |
Scientific American Science & Medicine Magazine March/April 1994 (Vol. 1 No. 1, Viral Hepatitis, Natriuretic Peptides, HIV Vaccine, Vitamin E) by various (Author) Great informational magazine! Full color as well as b/w illustrations, diagrams and photos. |
| © 2009 BrightSurf.com |